| abstract |
Combinations of a CDK 4/6 inhibitor and a glutaminase inhibitor are useful for the treatment of cancer, particularly: colon cancer, breast cancer, melanoma, glioblastoma, osteosarcoma, cervical cancer, lymphoma, squamous cell skin cancer, and glioma. A preferred CDK 4/6 inhibitor is 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin- 2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one hydrochloride. Preferred glutaminase inhibitors are bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide and 2-(pyridin-2- yl)-N-(5-(4-(6-(2-(3-(trifluoromethoxy)phenyl)acetamido)pyridazin-3-yl)butyl)-1,3,4- thiadiazol-2-yl)acetamide. The combinations present a synergistic effect in the treatment of mammals, including humans. The administration may be simultaneous, separated or sequential. |